Should autologous HSCT be a first-line option in highly active MS? No

Research output: Contribution to journal › Article › peer-review

Access to Document

TY - JOUR

T1 - Should autologous HSCT be a first-line option in highly active MS? No

AU - Toljan, Karlo

AU - Jacob, Anu

PY - 2026

Y1 - 2026

UR - https://www.scopus.com/pages/publications/105036850477

U2 - 10.1177/13524585261439664

DO - 10.1177/13524585261439664

M3 - Article

AN - SCOPUS:105036850477

SN - 1352-4585

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

ER -